Bristol-Myers Squibb 4th-qtr beats estimates on strong Opdivo and Eliquis sales

28 January 2016

Bristol-Myers Squibb (NYSE: BMY) on Thursday posted fourth-quarter 2015 results ahead of estimates, driven by strong sales of its cancer drug Opdivo (nivolumab), and blood thinner Eliquis (apixaban), and said it sees earnings in 2016 above market expectations.

The company reported a fourth-quarter net loss of $138 million, or $0.08 per share, compared with net earnings of $13 million, or $0.01 per share, a year ago. Excluding special items, including a charge related to the acquisition of Five Prime Therapeutics, and Cardioxyl Pharmaceuticals the company posted net earnings of $647 million, or $0.38 per share.

Revenue rose to $4.3 billion, up 1% compared with the same period last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK